Retrophin to pay $3 million in U.S. lawsuit over Shkreli's tenure

NEW YORK, Feb 3 (Reuters) - Retrophin Inc has agreed to pay $3 million to resolve a lawsuit by investors accusing the pharmaceutical company of failing to disclose various transactions that benefited former Chief Executive Officer Martin Shkreli, who has since been indicted for securities fraud.